BOT burn $3-4M/Qtr. have $37.3M in hand and expect ~$6M R&D...

BOT burn $3-4M/Qtr. have $37.3M in hand and expect ~$6M R&D rebate. - from the A.Kohler interview, extract:

You went through your cash before which is great, just to be clear on it you’ve got $37million in cash in the bank, how much are you burning?
It’s about $3 to $4 million a quarter.
Is that going to stay the same as you go into phase 3 now or is that going to cost more?
That would be additional money that the company would raise then for those phase 3 clinical trials.
How much would you have to raise?
It depends upon whatever the clinical trial is going to cost and until we engage with the FDA we won’t know the size of the study and the size of the study dictates where the cost is going to be.


no specific mention of a "CR" here, but word from the AGM was more clearly a CR is the likely mode.

phase 3 for BTX 1503 will be expensive no doubt, but BOT can comfortably afford to wait until post BTX 1204 results to raise...

and perhaps the results will present alternatives.